<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37499240</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Multidisciplinary approach to lupus nephritis: Clinical pearls, pitfalls, and positioning of newly-approved agents.</ArticleTitle><Pagination><StartPage>1155</StartPage><EndPage>1163</EndPage><MedlinePgn>1155-1163</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231191944</ELocationID><Abstract><AbstractText>Lupus nephritis (LN) is a major course of morbidity and mortality in patients with systemic lupus erythematosus (SLE), best managed by a multidisciplinary group. To this end, we gathered a group of rheumatologists, nephrologists and a nephropathologist to review current evidence regarding diagnosis and management of LN. In this consensus paper, we summarize the key points from this meeting and provide practice guidelines for the management of kidney involvement in SLE, in view of emerging new data concerning novel agents approved recently. Renal biopsy is indispensable for the management of LN. Yet, important pearls and pitfalls need to be considered regarding indications and interpretation, which are summarized in informative tables. In new-onset LN, experts agreed that, although belimumab may be added from disease onset, patients with moderate to severe proliferative nephritis (defined as: NIH activity index &gt; 5 plus &#x2265; 1 of the following: (i) NIH chronicity index &gt; 2, (ii) proteinuria &gt; 3&#xa0;<i>g</i>/24&#xa0;h, and (iii) increase in serum creatinine &gt; 20%) may be more likely to benefit the most. In all other patients who have already started standard-of-care treatment with either mycophenolate mofetil (MMF) or cyclophosphamide (CY), belimumab could be considered in cases with an inadequate clinical response by 3&#xa0;months, or in cases that experience a nephritic flare following initial response, or have an inability to reduce the dose of glucocorticoids. In all circumstances, the drug should be given as add-on therapy, that is, in combination with a standard-of-care therapy (MMF or CY). Voclosporin could be considered for up to 3&#xa0;years, in combination with MMF, in patients with heavy proteinuria (well above the nephrotic range), wherein a quick reduction of protein loss in urine is desirable to avoid the complications of the nephrotic syndrome, either as part of the initial regimen, or in cases of inadequate reduction of proteinuria with MMF. In view of the potential scarring effects, long-term administration beyond the first year requires further documentation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fanouriakis</LastName><ForeName>Antonis</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2696-031X</Identifier><AffiliationInfo><Affiliation>Rheumatology and Clinical Immunology, "Attikon" University Hospital of Athens, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation><Identifier Source="RINGGOLD">68993</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertsias</LastName><ForeName>George</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5299-1406</Identifier><AffiliationInfo><Affiliation>Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Herakilon, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular Biology and Biotechnology, Foundation or Research and Technology - Hellas (FORTH), Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liapis</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>First Department of Pathology, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation><Identifier Source="RINGGOLD">68993</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinaki</LastName><ForeName>Smaragdi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Renal Transplantation, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation><Identifier Source="RINGGOLD">68993</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papagianni</LastName><ForeName>Aikaterini</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation><Identifier Source="RINGGOLD">37782</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stangou</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation><Identifier Source="RINGGOLD">37782</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garyfallos</LastName><ForeName>Alexandros</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>4th Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation><Identifier Source="RINGGOLD">37782</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lionaki</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1643-8923</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, "Attikon" University Hospital of Athens, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation><Identifier Source="RINGGOLD">68993</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tektonidou</LastName><ForeName>Maria G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0003-2238-0975</Identifier><AffiliationInfo><Affiliation>First Department of Propaedeutic Internal Medicine, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation><Identifier Source="RINGGOLD">68993</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boletis</LastName><ForeName>John N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Renal Transplantation, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation><Identifier Source="RINGGOLD">68993</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boumpas</LastName><ForeName>Dimitrios T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Rheumatology and Clinical Immunology, "Attikon" University Hospital of Athens, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation><Identifier Source="RINGGOLD">68993</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Foundation of the Academy of Athens, Laboratory of Autoimmunity and Inflammation, Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011507" MajorTopicYN="N">Proteinuria</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lupus nephritis</Keyword><Keyword MajorTopicYN="N">renal lupus</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>27</Day><Hour>19</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>27</Day><Hour>16</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37499240</ArticleId><ArticleId IdType="doi">10.1177/09612033231191944</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>